請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/99635完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 謝佳倩 | zh_TW |
| dc.contributor.advisor | Chia-Chien Hsieh | en |
| dc.contributor.author | 范揚舜 | zh_TW |
| dc.contributor.author | Yang-Shun Fan | en |
| dc.date.accessioned | 2025-09-17T16:13:10Z | - |
| dc.date.available | 2025-09-18 | - |
| dc.date.copyright | 2025-09-17 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-08-08 | - |
| dc.identifier.citation | Abd Radzak, S. M., Mohd Khair, S. Z. N., Ahmad, F., Patar, A., Idris, Z., & Mohamed Yusoff, A. A. (2022). Insights regarding mitochondrial DNA copy number alterations in human cancer (Review). Int J Mol Med, 50(2).
Abene, J., & Deng, J. (2025). Evaluating the role of dietary interventions in reducing chemotherapy toxicities in cancer patients: a systematic review. J Cancer Surviv. Ahmadirad, H., Omrani, M., Azmi, N., Saeidian, A. H., Jahromi, M. K., Mirtavoos-Mahyari, H., Akbarzadeh, M., Teymoori, F., Farhadnejad, H., & Mirmiran, P. (2025). Dietary phytochemical index and the risk of cancer: A systematic review and meta-analysis. PloS one, 20(4), e0319591. Alshareeda, A. T., Negm, O. H., Green, A. R., Nolan, C. C., Tighe, P., Albarakati, N., Sultana, R., Madhusudan, S., Ellis, I. O., & Rakha, E. A. (2015). KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. Br J Cancer, 112(12), 1929-1937. Altman, B. J., Stine, Z. E., & Dang, C. V. (2016). From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer, 16(11), 749. American Cancer Society. (2021) Types of Breast Cancer. Retrieved from:https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer.html Anders, C., & Carey, L. A. (2008). Understanding and treating triple-negative breast cancer. Oncology (Williston Park), 22(11), 1233-1239; discussion 1239-1240, 1243. Banna, M. N., Hasan, S., & Rochana, M. N. (2024). A Review on Phytochemical Compounds Used to Treatment of Breast Cancer. Glob Acad J Pharm Drug Res, 6. Bao, X., Zhang, J., Huang, G., Yan, J., Xu, C., Dou, Z., Sun, C., & Zhang, H. (2021). The crosstalk between HIFs and mitochondrial dysfunctions in cancer development. Cell Death & Disease, 12(2), 215. Barron, C. C., Bilan, P. J., Tsakiridis, T., & Tsiani, E. (2016). Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism, 65(2), 124-139. Ben-Dror, J., Shalamov, M., & Sonnenblick, A. (2022). The History of Early Breast Cancer Treatment. Genes (Basel), 13(6). Caffa, I., Spagnolo, V., Vernieri, C., Valdemarin, F., Becherini, P., Wei, M., Brandhorst, S., Zucal, C., Driehuis, E., Ferrando, L., Piacente, F., Tagliafico, A., Cilli, M., Mastracci, L., Vellone, V. G., Piazza, S., Cremonini, A. L., Gradaschi, R., Mantero, C., . . . Nencioni, A. (2020). Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature, 583(7817), 620-624. Cam, A., & de Mejia, E. G. (2012). RGD‐peptide lunasin inhibits Akt‐mediated NF‐κB activation in human macrophages through interaction with the αVβ3 integrin. Molecular nutrition & food research, 56(10), 1569-1581. Chang, Y. J., Hou, Y. C., Chen, L. J., Wu, J. H., Wu, C. C., Chang, Y. J., & Chung, K. P. (2017). Is vegetarian diet associated with a lower risk of breast cancer in Taiwanese women? BMC Public Health, 17(1), 800. Chen, Y., Zhang, J., Zhang, M., Song, Y., Zhang, Y., Fan, S., Ren, S., Fu, L., Zhang, N., Hui, H., & Shen, X. (2021). Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α. Clin Transl Med, 11(11), e577. Dong, H., Jia, W., Meng, W., Zhang, R., Qi, Z., Chen, Z., Xie, S., Min, J., Liu, L., & Shen, J. (2024). DAB2IP inhibits glucose uptake by modulating HIF-1α ubiquitination under hypoxia in breast cancer. Oncogenesis, 13(1), 20. Fan, X., Qin, P., Hao, Y., Guo, H., Blecker, C., Everaert, N., & Ren, G. (2020). Overexpression of soybean-derived lunasin in wheat and assessment of its anti-proliferative activity in colorectal cancer HT-29 cells. International Journal of Molecular Sciences, 21(24), 9594. Feng, J., Wu, L., Ji, J., Chen, K., Yu, Q., Zhang, J., Chen, J., Mao, Y., Wang, F., Dai, W., Xu, L., Wu, J., & Guo, C. (2019). PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma. J Exp Clin Cancer Res, 38(1), 204. Fernández-Tomé, S., Xu, F., Han, Y., Hernández-Ledesma, B., & Xiao, H. (2020). Inhibitory effects of peptide lunasin in colorectal cancer HCT-116 cells and their tumorsphere-derived subpopulation. International Journal of Molecular Sciences, 21(2), 537. Ferrere, G., Tidjani Alou, M., Liu, P., Goubet, A. G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., Daillère, R., Thelemaque, C., Grajeda-Iglesias, C., Alves Costa Silva, C., Aprahamian, F., Lefevre, D., Zhao, L., Ryffel, B., Colomba, E., Arnedos, M., . . . Zitvogel, L. (2021). Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight, 6(2). Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Rigoni, A., Vacchelli, E., Michaud, M., Zischka, H., Castedo, M., & Kroemer, G. (2010). Mitochondrial gateways to cancer. Molecular aspects of medicine, 31(1), 1-20. García-Nebot, M. J., Recio, I., & Hernández-Ledesma, B. (2014). Antioxidant activity and protective effects of peptide lunasin against oxidative stress in intestinal Caco-2 cells. Food and Chemical Toxicology, 65, 155-161. Gu, L., Ye, P., Li, H., Wang, Y., Xu, Y., Tian, Q., Lei, G., Zhao, C., Gao, Z., & Zhao, W. (2019). Lunasin attenuates oxidant‐induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE−/− mice by up‐regulating heme oxygenase‐1 via PI3K/Akt/Nrf2/ARE pathway. The FASEB Journal, 33(4), 4836-4850. Guerra, F., Guaragnella, N., Arbini, A. A., Bucci, C., Giannattasio, S., & Moro, L. (2017). Mitochondrial Dysfunction: A Novel Potential Driver of Epithelial-to-Mesenchymal Transition in Cancer. Front Oncol, 7, 295. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discov, 12(1), 31-46. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. cell, 100(1), 57-70. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. cell, 144(5), 646-674. Hernández-Ledesma, B., Hsieh, C.-C., & de Lumen, B. O. (2009). Antioxidant and anti-inflammatory properties of cancer preventive peptide lunasin in RAW 264.7 macrophages. Biochemical and biophysical research communications, 390(3), 803-808. Hernández-Ledesma, B., Hsieh, C. C., & de Lumen, B. O. (2011). Relationship between lunasin's sequence and its inhibitory activity of histones H3 and H4 acetylation. Mol Nutr Food Res, 55(7), 989-998. Hsieh, C.-C., Chou, M.-J., & Wang, C.-H. (2017). Lunasin attenuates obesity-related inflammation in RAW264. 7 cells and 3T3-L1 adipocytes by inhibiting inflammatory cytokine production. PloS one, 12(2), e0171969. Hsieh, C. C., Hernández-Ledesma, B., Jeong, H. J., Park, J. H., & de Lumen, B. O. (2010). Complementary roles in cancer prevention: protease inhibitor makes the cancer preventive peptide lunasin bioavailable. PloS one, 5(1), e8890. Hsieh, C. C., Martínez‐Villaluenga, C., de Lumen, B. O., & Hernández‐Ledesma, B. (2018). Updating the research on the chemopreventive and therapeutic role of the peptide lunasin. Journal of the Science of Food and Agriculture, 98(6), 2070-2079. Hsieh, C. C., Wu, C. H., Peng, S. H., & Chang, C. H. (2023). Seed-derived peptide lunasin suppressed breast cancer cell growth by regulating inflammatory mediators, aromatase, and estrogen receptors. Food Nutr Res, 67. Hsu, C. C., Tseng, L. M., & Lee, H. C. (2016). Role of mitochondrial dysfunction in cancer progression. Exp Biol Med (Maywood), 241(12), 1281-1295. Jawarneh, S., & Talib, W. H. (2022). Combination of ashwagandha water extract and intermittent fasting as a therapy to overcome cisplatin resistance in breast cancer: an in vitro and in vivo study. Frontiers in Nutrition, 9, 863619. Jeong, H. J., Jeong, J. B., Kim, D. S., & de Lumen, B. O. (2007). Inhibition of core histone acetylation by the cancer preventive peptide lunasin. J Agric Food Chem, 55(3), 632-637. Jin, H. R., Wang, J., Wang, Z. J., Xi, M. J., Xia, B. H., Deng, K., & Yang, J. L. (2023). Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol, 16(1), 103. Jin, J., Byun, J. K., Choi, Y. K., & Park, K. G. (2023). Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med, 55(4), 706-715. Kalam, F., James, D. L., Li, Y. R., Coleman, M. F., Kiesel, V. A., Cespedes Feliciano, E. M., Hursting, S. D., Sears, D. D., & Kleckner, A. S. (2023). Intermittent fasting interventions to leverage metabolic and circadian mechanisms for cancer treatment and supportive care outcomes. J Natl Cancer Inst Monogr, 2023(61), 84-103. Keating, E., & Martel, F. (2018). Antimetabolic Effects of Polyphenols in Breast Cancer Cells: Focus on Glucose Uptake and Metabolism. Front Nutr, 5, 25. Khajah, M. A., Khushaish, S., & Luqmani, Y. A. (2022). Glucose deprivation reduces proliferation and motility, and enhances the anti-proliferative effects of paclitaxel and doxorubicin in breast cell lines in vitro. PloS one, 17(8), e0272449. Kleckner, A. S., Altman, B. J., Reschke, J. E., Kleckner, I. R., Culakova, E., Dunne, R. F., Mustian, K. M., & Peppone, L. J. (2022). Time-restricted Eating to Address Cancer-related Fatigue among Cancer Survivors: A Single-arm Pilot Study. J Integr Oncol, 11(5). Kocianova, E., Piatrikova, V., & Golias, T. (2022). Revisiting the Warburg Effect with Focus on Lactate. Cancers (Basel), 14(24). Koundouros, N., & Poulogiannis, G. (2020). Reprogramming of fatty acid metabolism in cancer. Br J Cancer, 122(1), 4-22. Krstic, J., Reinisch, I., Schindlmaier, K., Galhuber, M., Riahi, Z., Berger, N., Kupper, N., Moyschewitz, E., Auer, M., & Michenthaler, H. (2022). Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. Science advances, 8(3), eabh2635. Laudański, P., Swiatecka, J., Kovalchuk, O., & Wołczyński, S. (2003). Expression of GLUT1 gene in breast cancer cell lines MCF-7 and MDA-MB-231. Ginekol Pol, 74(9), 782-785. Li, J., Tong, D., & Lin, J. (2022). Current status of cancer starvation therapy. Zhejiang da xue xue bao. Yi xue ban= Journal of Zhejiang University. Medical sciences, 51(2), 241-250. Li, X., Peng, X., Li, Y., Wei, S., He, G., Liu, J., Li, X., Yang, S., Li, D., Lin, W., Fang, J., Yang, L., & Li, H. (2024). Glutamine addiction in tumor cell: oncogene regulation and clinical treatment. Cell Commun Signal, 22(1), 12. Luo, Y., Ma, J., & Lu, W. (2020). The Significance of Mitochondrial Dysfunction in Cancer. Int J Mol Sci, 21(16). Macheda, M. L., Rogers, S., & Best, J. D. (2005). Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol, 202(3), 654-662. Macleod, K. F. (2020). Mitophagy and mitochondrial dysfunction in cancer. Annual Review of Cancer Biology, 4(1), 41-60. Mercier, B. D., Tizpa, E., Philip, E. J., Feng, Q., Huang, Z., Thomas, R. M., Pal, S. K., Dorff, T. B., & Li, Y. R. (2022). Dietary Interventions in Cancer Treatment and Response: A Comprehensive Review. Cancers, 14(20), 5149. Odani, S., Koide, T., & Ono, T. (1987). Amino acid sequence of a soybean (Glycine max) seed polypeptide having a poly (L-aspartic acid) structure. Journal of Biological Chemistry, 262(22), 10502-10505. Pateras, I. S., Williams, C., Gianniou, D. D., Margetis, A. T., Avgeris, M., Rousakis, P., Legaki, A.-I., Mirtschink, P., Zhang, W., & Panoutsopoulou, K. (2023). Short term starvation potentiates the efficacy of chemotherapy in triple negative breast cancer via metabolic reprogramming. Journal of Translational Medicine, 21(1), 169. Pavlova, N. N., & Thompson, C. B. (2016). The Emerging Hallmarks of Cancer Metabolism. Cell Metab, 23(1), 27-47. Pelletier, J., Thomas, G., & Volarević, S. (2018). Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer, 18(1), 51-63. Roy, M., Fowler, A. M., Ulaner, G. A., & Mahajan, A. (2023). Molecular Classification of Breast Cancer. PET Clin, 18(4), 441-458. Samec, M., Liskova, A., Koklesova, L., Samuel, S. M., Zhai, K., Buhrmann, C., Varghese, E., Abotaleb, M., Qaradakhi, T., Zulli, A., Kello, M., Mojzis, J., Zubor, P., Kwon, T. K., Shakibaei, M., Büsselberg, D., Sarria, G. R., Golubnitschaja, O., & Kubatka, P. (2020). Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism. Epma j, 11(3), 377-398. Scherbakov, A. M., Sorokin, D. V., Omelchuk, O. A., Shchekotikhin, A. E., & Krasil’nikov, M. A. (2021). Glucose starvation greatly enhances antiproliferative and antiestrogenic potency of oligomycin A in MCF-7 breast cancer cells. Biochimie, 186, 51-58. Seligman, H. K., Angell, S. Y., Berkowitz, S. A., Elkind, M. S., Hager, K., Moise, N., Posner, H., Muse, J., Odoms-Young, A., & Ridberg, R. (2025). A Systematic Review of “Food Is Medicine” Randomized Controlled Trials for Noncommunicable Disease in the United States: A Scientific Statement From the American Heart Association. Circulation. Shabkhizan, R., Haiaty, S., Moslehian, M. S., Bazmani, A., Sadeghsoltani, F., Saghaei Bagheri, H., Rahbarghazi, R., & Sakhinia, E. (2023). The Beneficial and Adverse Effects of Autophagic Response to Caloric Restriction and Fasting. Adv Nutr, 14(5), 1211-1225. Siddiqui, F. A., Prakasam, G., Chattopadhyay, S., Rehman, A. U., Padder, R. A., Ansari, M. A., Irshad, R., Mangalhara, K., Bamezai, R. N. K., Husain, M., Ali, S. M., & Iqbal, M. A. (2018). Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition. Sci Rep, 8(1), 8323. Su, Z., Liu, Y., Xia, Z., Rustgi, A. K., & Gu, W. (2024). An unexpected role for the ketogenic diet in triggering tumor metastasis by modulating BACH1-mediated transcription. Sci Adv, 10(23), eadm9481. Sun, J., Meng, H., Yao, L., Lv, M., Bai, J., Zhang, J., Wang, L., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2017). Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients. Clin Cancer Res, 23(20), 6113-6119. Tiwari, S., Sapkota, N., & Han, Z. (2022). Effect of fasting on cancer: A narrative review of scientific evidence. Cancer Sci, 113(10), 3291-3302. Trayes, K. P., & Cokenakes, S. E. H. (2021). Breast Cancer Treatment. Am Fam Physician, 104(2), 171-178. Wang, J., Ye, C., Chen, C., Xiong, H., Xie, B., Zhou, J., Chen, Y., Zheng, S., & Wang, L. (2017). Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget, 8(10), 16875-16886. Wang, J. X., Choi, S. Y. C., Niu, X., Kang, N., Xue, H., Killam, J., & Wang, Y. (2020). Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity. Int J Mol Sci, 21(21). Wang, P., Song, M., Eliassen, A. H., Wang, M., Fung, T. T., Clinton, S. K., Rimm, E. B., Hu, F. B., Willett, W. C., Tabung, F. K., & Giovannucci, E. L. (2023). Optimal dietary patterns for prevention of chronic disease. Nat Med, 29(3), 719-728. Wang, Y., Gao, S., Xu, Y., Tang, Z., & Liu, S. (2023). Characterization of starvation response‐related genes for predicting prognosis in breast cancer. Cancer Science, 114(8), 3144-3161. Wei, R., Mao, L., Xu, P., Zheng, X., Hackman, R. M., Mackenzie, G. G., & Wang, Y. (2018). Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models. Food Funct, 9(11), 5682-5696. Xiao, Y. L., Gong, Y., Qi, Y. J., Shao, Z. M., & Jiang, Y. Z. (2024). Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential. Signal Transduct Target Ther, 9(1), 59. World Cancer Research Fund (2025) Retrieved from:https://www.wcrf.org/research-policy/library/dietary-and-lifestyle-patterns-and-cancer-prevention/?utm_source=World+Cancer+Research+Fund+International&utm_campaign=725f1b366c-INT-e-news-Apr-2025&utm_medium=email&utm_term=0_8e546f8c30-836973c580-275645968 World Health Organization. (2024, March 13). Breast cancer. Retrieved from:https://www.who.int/news-room/fact-sheets/detail/breast-cancer Yang, K., Wang, X., Song, C., He, Z., Wang, R., Xu, Y., Jiang, G., Wan, Y., Mei, J., & Mao, W. (2023). The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics, 13(6), 1774-1808. Yang, T. L., Tsai, C. H., Su, Y. W., Chang, Y. C., Lee, F., Huang, T. Y., Li, F. Y., & Yang, P. S. (2025). Combining KPNA2 and FOXM1 Expression as Prognostic Markers and Therapeutic Targets in Hormone Receptor-Positive, HER2-Negative Breast Cancer. Cancers (Basel), 17(4). Ying, B., Xu, W., Nie, Y., & Li, Y. (2022). HSPA8 Is a New Biomarker of Triple Negative Breast Cancer Related to Prognosis and Immune Infiltration. Dis Markers, 2022, 8446857. Younas, M., Hano, C., Giglioli-Guivarc'h, N., & Abbasi, B. H. (2018). Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives. RSC Adv, 8(52), 29714-29744. Zhang, D., Tang, Z., Huang, H., Zhou, G., Cui, C., Weng, Y., Liu, W., Kim, S., Lee, S., Perez-Neut, M., Ding, J., Czyz, D., Hu, R., Ye, Z., He, M., Zheng, Y. G., Shuman, H. A., Dai, L., Ren, B., . . . Zhao, Y. (2019). Metabolic regulation of gene expression by histone lactylation. Nature, 574(7779), 575-580. Zhao, S. F., Leng, J. F., Xie, S. S., Zhu, L. Q., Zhang, M. Y., Kong, L. Y., & Yin, Y. (2024). Design, synthesis and biological evaluation of CDC20 inhibitors for treatment of triple-negative breast cancer. Eur J Med Chem, 268, 116204. Zhu, Y., Li, H., & Wang, X. (2017). Lunasin abrogates monocytes to endothelial cells. Molecular Immunology, 92, 146-150. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/99635 | - |
| dc.description.abstract | 乳癌是全球女性最常見的惡性腫瘤之一。天然物具有多元的生理活性且低毒性副作用，已廣泛被研究於化學預防。其中lunasin是一具有生物活性的種子胜肽，其作用包括抗腫瘤；近年健康意識抬頭，改變生活型態預防疾病成為主流，其中飲食限制也備受關注，研究顯示短期禁食也可抑制癌細胞的生長。本研究欲探討lunasin與間歇性禁食 (short-term starvation, STS) 處理對於乳癌細胞生長的影響機制。實驗包含兩部分，第一部分為lunasin處理兩株乳癌細胞MCF-7與MDA-MB-231與一株正常乳腺上皮細胞MCF-10A，結果顯示lunasin可抑制MCF-7細胞之乳酸與ATP生成之趨勢，由於效應未達顯著，無法推斷透過瓦式效應。因此第二部分加入STS設計，以期提高抗癌的效果作用，分組為lunasin或STS或兩者合併處理乳癌細胞。首先建立與使用的禁食條件，在低葡萄糖培養基 (1 g/L 葡萄糖，1% FBS) 中相較於無葡萄糖培養基 (0 g/L 葡萄糖，1% FBS)，lunasin、STS與合併處理相較控制組，顯著降低兩株乳癌細胞的生長，但不影響正常細胞生長，因此選擇低糖培養基進行後續實驗。在乳癌細胞乳酸及ATP生成結果，lunasin與STS處理後沒有顯著差異，且合併組也未能有協同效應，主要變化是來自於STS的營養缺乏而非lunasin。而在轉錄體分析中，兩株乳癌細胞在STS組及合併處理組對轉錄體表現的影響皆較lunasin組顯著，顯示營養缺乏為主要影響因素。在Gene Set Enrichment Analysis (GSEA) 分析中，乳癌細胞於STS組中顯著富集細胞週期、轉錄後修飾、蛋白質合成及核輸送等路徑。根據上述，lunasin及STS處理對抑制乳癌細胞乳酸與ATP的生成效果有限，而合併處理也未展現協同效應。在轉錄體層面，STS處理是抑制乳癌細胞生長的主要因素，透過比對熱點圖篩選出具潛力的關鍵調控基因，提供未來研究相關機制的標的。 | zh_TW |
| dc.description.abstract | Breast cancer is the most common cancer among women worldwide. Natural compounds with bioactivity and low toxicity are widely studied for cancer prevention. Lunasin, a bioactive seed peptide, has demonstrated anti-tumor properties. In recent years, lifestyle interventions such as dietary restriction have gained attention for disease prevention. Short-term starvation (STS) has been shown to inhibit cancer cell growth. This study investigated the effects and mechanisms of lunasin and STS on breast cancer cell growth. The study included two parts, in the first part, breast cancer cells MCF-7, MDA-MB-231 and normal breast epithelial cell MCF-10A were treated with lunasin. The results showed that lunasin slightly reduced lactate and ATP production in MCF-7 cells; however, the effects can’t support inhibition of the Warburg effect. Therefore, STS was added in the second part to enhance potential anti-cancer activity. Cells were treated with lunasin, STS, or combination treatment. Low-glucose STS (1 g/L glucose with 1% FBS) was selected based on its ability to inhibit the growth to both cancer cell lines without affecting normal cells. However, lactate and ATP levels weren't significantly different, and no synergistic effect in combination treatment, suggesting that the metabolic effects were primarily driven by STS. Transcriptome analysis revealed that STS induced most of the transcriptional changes, with little added effect from lunasin. GSEA results showed significant enrichment pathways related to cell cycle, post-transcriptional modification, protein synthesis and nucleocytoplasmic transport in STS-treated groups. In conclusion, lunasin and STS treatment had limited effects on lactate and ATP production in breast cancer cells, and no synergistic in combination treatment. Additionally, no glycolysis-related pathways were enriched in the transcriptomic data. STS appeared to be the major contributor to growth inhibition in transcriptional level. Potential regulatory genes were identified from heatmap, offering targets for future mechanistic studies. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-09-17T16:13:09Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-09-17T16:13:10Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 摘要 i
Abstract ii 目次 iii 圖次 vi 表次 vii 第一章、 文獻探討 1 第一節、 乳癌 1 一、 流行病學與臨床分類 1 二、 罹患乳癌的危險因子 2 三、 治療方式 3 第二節、 癌症之代謝重整 4 一、 癌症的特徵 4 二、 癌細胞之醣類代謝 4 三、 癌細胞之脂類代謝 6 四、 Glutamine代謝異常 6 五、 粒線體功能受損 7 第三節、 飲食調整對癌症發展的影響 9 一、 飲食調整之概念與應用 9 二、 飲食干預策略 9 三、 短期飢餓 (short-term starvation, STS) 10 四、 STS與乳癌相關研究 11 五、 STS與Warburg effect 11 第四節、 天然植化素與乳癌 12 一、 飲食因子與癌症 12 二、 Lunasin簡介 12 三、 Lunasin的抗癌活性 13 四、 Lunasin的抗發炎及抗氧化活性 14 五、 其他植化素與乳癌 15 六、 植化素與Warburg effect 16 第二章、 實驗動機與實驗設計 17 第一節、 研究動機與假說 17 第二節、 實驗架構 18 第三章、 實驗材料與方法 19 第一節、 實驗儀器設備 19 一、 實驗室儀器設備 19 二、 拋棄式無菌耗材 19 第二節、 實驗材料與方法 20 一、 細胞培養 20 二、 短期禁食 21 三、 細胞之存活率測驗 21 四、 細胞之葡萄糖攝取 22 五、 細胞之乳酸生產試驗 22 六、 細胞之ATP生產試驗 23 七、 RNA抽取 24 八、 RNA定序分析 25 九、 統計分析 26 第五章、 實驗結果 27 第一節、 Lunasin單獨處理對乳癌細胞生長之影響 27 第二節、 Lunasin單獨處理對乳癌細胞葡萄糖代謝之影響 29 第三節、 建立乳癌細胞短期禁食的實驗條件 31 第四節、 Lunasin、短期禁食與合併處理對乳癌細胞葡萄糖代謝之影響 33 第五節、 Lunasin、短期禁食與合併處理對乳癌細胞轉錄體之影響 35 第六章、 討論 46 第一節、 Lunasin單獨處理對乳癌細胞葡萄糖代謝之影響 46 第二節、 Lunasin、短期禁食與合併處理對乳癌細胞存活率及葡萄糖代謝之影響 47 第三節、 Lunasin、短期禁食與合併處理對乳癌細胞轉錄體之影響 48 一、 乳癌細胞之GSEA分析 48 第七章、 結論 50 第八章、 參考文獻 51 第九章、 附錄 58 第一節、 Lunasin、短期禁食與合併處理對乳癌細胞轉錄體之ORA分析 58 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | Lunasin | zh_TW |
| dc.subject | 短期禁食 | zh_TW |
| dc.subject | 乳癌 | zh_TW |
| dc.subject | 瓦式效應 | zh_TW |
| dc.subject | RNA定序分析 | zh_TW |
| dc.subject | 細胞週期 | zh_TW |
| dc.subject | breast cancer | en |
| dc.subject | Lunasin | en |
| dc.subject | cell cycle | en |
| dc.subject | RNA-sequencing | en |
| dc.subject | Warburg effect | en |
| dc.subject | STS | en |
| dc.title | 以轉錄體分析lunasin胜肽與短期禁食對乳癌細胞之影響 | zh_TW |
| dc.title | Transcriptomic analysis of the effects of lunasin peptide and short-term starvation on breast cancer cells | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 林璧鳳;羅凱尹;吳啟豪 | zh_TW |
| dc.contributor.oralexamcommittee | Bi-Fong Lin;Kai-Yin Lo;Chi-Hao Wu | en |
| dc.subject.keyword | Lunasin,短期禁食,乳癌,瓦式效應,RNA定序分析,細胞週期, | zh_TW |
| dc.subject.keyword | Lunasin,STS,breast cancer,Warburg effect,RNA-sequencing,cell cycle, | en |
| dc.relation.page | 64 | - |
| dc.identifier.doi | 10.6342/NTU202503758 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2025-08-12 | - |
| dc.contributor.author-college | 生命科學院 | - |
| dc.contributor.author-dept | 生化科技學系 | - |
| dc.date.embargo-lift | 2030-08-04 | - |
| 顯示於系所單位： | 生化科技學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-2.pdf 未授權公開取用 | 3.28 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。